Medtide Inc. (HKG:3880)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
21.80
+0.62 (2.93%)
Apr 29, 2026, 3:59 PM HKT
Market Cap 3.09B
Revenue (ttm) 634.40M
Net Income (ttm) 241.89M
Shares Out 141.80M
EPS (ttm) 1.81
PE Ratio 12.01
Forward PE 9.49
Dividend n/a
Ex-Dividend Date n/a
Volume 100,800
Average Volume 104,185
Open 21.18
Previous Close 21.18
Day's Range 21.18 - 21.90
52-Week Range 21.04 - 41.72
Beta n/a
RSI 44.40
Earnings Date May 29, 2026

About Medtide

Medtide Inc., a contract research, development, and manufacturing company, provides early-stage discovery, preclinical research, clinical development, and commercial-stage production services. It offers peptide new chemical entity discovery synthesis, peptide chemistry, manufacturing, and control development and commercial manufacturing services. The company focuses on developing oral and/or injectable glucagon, such as peptide-1 (GLP-1) molecule products. Its research and development technology platform include OmniPeptSynth, PeptiConjuX, Pept... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2020
Employees 566
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 3880
Full Company Profile

Financial Performance

In 2025, Medtide's revenue was 570.09 million, an increase of 28.91% compared to the previous year's 442.23 million. Earnings were 217.37 million, an increase of 267.35%.

Financial numbers in CNY Financial Statements

News

There is no news available yet.